Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

NHS to appeal High Court PrEP commissioning ruling

NHS to appeal High Court PrEP commissioning ruling PharmacoEconomics & Outcomes News 759, p6 - 13 Aug 2016 NHS to appeal High Court PrEP commissioning ruling NHS England has decided it will appeal a High Court ruling that it had the responsibility to commission pre- exposure prophylaxis (PrEP) for the prevention of HIV, rather than just local commissioning groups. This ruling overturns NHS England’s position that it took in March, and reiterated in May , after taking legal advice that suggested NHS England did not have the legal power to commission PrEP and doing so may present risk of legal challenge from proponents of other ’candidate’ treatments. Given PrEP would cost £10 £20 million a year, NHS England has said that pending a ruling from the Court of Appeal, it is only able to confirm funding for new treatments and services in levels one and two of the Clinical Priorities Advisory Group (CPAG) prioritisation round, but not those in level three or four. The CPAG will be asked to re-run the prioritisation process for drugs and treatments previously placed in levels 3, 4 and 5 after receiving ’best and final’ prices from the manufacturers as well as Gilead (the pharmaceutical company marketing the PrEP drug, Truvada) so http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png PharmacoEconomics & Outcomes News Springer Journals

NHS to appeal High Court PrEP commissioning ruling

PharmacoEconomics & Outcomes News , Volume 759 (1) – Aug 13, 2016
Download PDF
1 page

NHS to appeal High Court PrEP commissioning ruling

Abstract

PharmacoEconomics & Outcomes News 759, p6 - 13 Aug 2016 NHS to appeal High Court PrEP commissioning ruling NHS England has decided it will appeal a High Court ruling that it had the responsibility to commission pre- exposure prophylaxis (PrEP) for the prevention of HIV, rather than just local commissioning groups. This ruling overturns NHS England’s position that it took in March, and reiterated in May , after taking legal advice that suggested NHS England did not have the legal...
Loading next page...
 
/lp/springer-journals/nhs-to-appeal-high-court-prep-commissioning-ruling-Jnf8OWF556

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Springer Journals
Copyright
Copyright © 2016 by Springer International Publishing Switzerland
Subject
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Public Health
ISSN
1173-5503
eISSN
1179-2043
DOI
10.1007/s40274-016-3271-2
Publisher site
See Article on Publisher Site

Abstract

PharmacoEconomics & Outcomes News 759, p6 - 13 Aug 2016 NHS to appeal High Court PrEP commissioning ruling NHS England has decided it will appeal a High Court ruling that it had the responsibility to commission pre- exposure prophylaxis (PrEP) for the prevention of HIV, rather than just local commissioning groups. This ruling overturns NHS England’s position that it took in March, and reiterated in May , after taking legal advice that suggested NHS England did not have the legal power to commission PrEP and doing so may present risk of legal challenge from proponents of other ’candidate’ treatments. Given PrEP would cost £10 £20 million a year, NHS England has said that pending a ruling from the Court of Appeal, it is only able to confirm funding for new treatments and services in levels one and two of the Clinical Priorities Advisory Group (CPAG) prioritisation round, but not those in level three or four. The CPAG will be asked to re-run the prioritisation process for drugs and treatments previously placed in levels 3, 4 and 5 after receiving ’best and final’ prices from the manufacturers as well as Gilead (the pharmaceutical company marketing the PrEP drug, Truvada) so

Journal

PharmacoEconomics & Outcomes News – Springer Journals

Published: Aug 13, 2016

There are no references for this article.